Loading company…
Tridek-One develops CD31 agonist molecules for autoimmune and inflammatory disorders.
Tridek-One researches molecules intended to restore immune balance by targeting activated cells. The biotechnology company was founded in 2018 and is based in Paris, France. It raised EUR 16 million in venture funding in September 2022, led by BB Pureos Bioventures, Bioqube Ventures and Bpifrance.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in